Literature DB >> 17976799

Community-acquired necrotizing soft tissue infections: a review of 122 cases presenting to a single emergency department over 12 years.

Bradley W Frazee1, Christopher Fee, Jeremy Lynn, Ralph Wang, Alan Bostrom, Cherie Hargis, Paul Moore.   

Abstract

PURPOSE: To characterize the Emergency Department (ED) presentation of necrotizing soft tissue infections (NSTI) and identify severity markers. PROCEDURES: Retrospective chart review of pathologically diagnosed NSTIs presenting to an urban ED from 1990-2001. Cases were identified from a surgical database, ICD-9 search and prospectively. Five Emergency Physicians (EPs) abstracted data using a standardized form. Severe NSTI was defined by any of the following: death, amputation, intensive care unit (ICU) stay >24 h, >300 cm(2) debrided. Severe and non-severe cases were compared using chi-square, Fisher's exact, and multivariate logistic regression testing.
FINDINGS: The 122 cases were characterized by: injection drug use, 80%; fever, 44%; systolic blood pressure (BP) <100 mm Hg, 21%; white blood cell count (WBC) >20 x 10(9)/L, 43%; median time to operation, 8.4 h; mortality, 16%. The managing EP suspected NSTI in 59%. A systolic BP <100 mm Hg, BUN >18 mg/dL, radiographic soft tissue gas, admission to a non-surgical service and clostridial species were independently associated with severe NSTI.
CONCLUSIONS: Pathologically defined NSTIs have a wide spectrum of ED presentations and early diagnosis remains difficult.

Entities:  

Mesh:

Year:  2007        PMID: 17976799     DOI: 10.1016/j.jemermed.2007.03.041

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  27 in total

1.  Necrotizing fasciitis: is the bacterial spectrum changing?

Authors:  Serafim Tsitsilonis; Claudia Druschel; Florian Wichlas; Norbert P Haas; Philipp Schwabe; Hermann-Josef Bail; Klaus-Dieter Schaser
Journal:  Langenbecks Arch Surg       Date:  2012-07-26       Impact factor: 3.445

Review 2.  Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes.

Authors:  Timo W Hakkarainen; Nicole M Kopari; Tam N Pham; Heather L Evans
Journal:  Curr Probl Surg       Date:  2014-06-12       Impact factor: 1.909

3.  Predictors of mortality for necrotizing soft-tissue infections: a retrospective analysis of 64 cases.

Authors:  Andreas Krieg; Levent Dizdar; Pablo Emilio Verde; Wolfram Trudo Knoefel
Journal:  Langenbecks Arch Surg       Date:  2014-01-11       Impact factor: 3.445

4.  Necrotizing fasciitis: treatment concepts and clinical results.

Authors:  M Leiblein; I Marzi; A L Sander; J H Barker; F Ebert; J Frank
Journal:  Eur J Trauma Emerg Surg       Date:  2017-05-08       Impact factor: 3.693

Review 5.  Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.

Authors:  Frederick L Altice; Adeeba Kamarulzaman; Vincent V Soriano; Mauro Schechter; Gerald H Friedland
Journal:  Lancet       Date:  2010-07-31       Impact factor: 79.321

6.  The roles of early surgery and comorbid conditions on outcomes of severe necrotizing soft-tissue infections.

Authors:  Rifat Latifi; Apar S Patel; David J Samson; Elizabeth H Tilley; Saranda Gashi; Roberto Bergamaschi; Ayman El-Menyar
Journal:  Eur J Trauma Emerg Surg       Date:  2018-05-22       Impact factor: 3.693

7.  Necrotising soft tissue infection in a UK metropolitan population.

Authors:  G E Glass; F Sheil; J C Ruston; P E M Butler
Journal:  Ann R Coll Surg Engl       Date:  2015-01       Impact factor: 1.891

8.  Fatal necrotizing fasciitis following elective inguinal hernia repair.

Authors:  S C Sistla; G Sankar; S Sistla
Journal:  Hernia       Date:  2009-12-10       Impact factor: 4.739

9.  Necrotizing fasciitis of the paraspinous muscles.

Authors:  Denise Law; Kapil R Dhingra
Journal:  West J Emerg Med       Date:  2010-02

Review 10.  Necrotizing fasciitis.

Authors:  Rukshini Puvanendran; Jason Chan Meng Huey; Shanker Pasupathy
Journal:  Can Fam Physician       Date:  2009-10       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.